A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-08

Study Completion Date

2027-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks.

Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment.

The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

NCT06926582

Psoriasis

NOT_YET_RECRUITING PHASE2

Treatment of Moderate to Severe Plaque Psoriasis

NCT06542614

Plaque Psoriasis

COMPLETED PHASE2

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

NCT01936688

Plaque-type Psoriasis

WITHDRAWN PHASE3

A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

NCT04316585

Psoriasis

COMPLETED PHASE1

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

NCT01729754

Plaque Psoriasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1：Low dose CS32582

The patient received low-dose CS32582 capsules BID or placebo for 4 weeks

Group Type EXPERIMENTAL

CS32582 capsule（low dose） or matched placebo

Intervention Type DRUG

CS32582 capsule（low dose） or matched placebo，4 weeks

Part 1：Hgh dose CS32582

The patient received high-dose CS32582 capsules BID or placebo for 4 weeks

Group Type EXPERIMENTAL

CS32582 capsule（high dose） or matched placebo

Intervention Type DRUG

CS32582 capsule（high dose） or matched placebo，4 weeks

Part 2：Low dose CS32582

The patient received low-dose CS32582 capsules BID or placebo for 12 weeks

Group Type EXPERIMENTAL

CS32582 capsule（low dose）

Intervention Type DRUG

CS32582 capsule（low dose），12 weeks

Part 2：Medium dose CS32582

The patient received medium-dose CS32582 capsules BID or placebo for 12 weeks

Group Type EXPERIMENTAL

CS32582 capsule（medium dose）

Intervention Type DRUG

CS32582 capsule（medium dose），12 weeks

Part 2：High dose CS32582

The patient received high-dose CS32582 capsules BID or placebo for 12 weeks

Group Type EXPERIMENTAL

CS32582 capsule（high dose）

Intervention Type DRUG

CS32582 capsule（high dose），12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CS32582 capsule（low dose） or matched placebo

CS32582 capsule（low dose） or matched placebo，4 weeks

Intervention Type DRUG

CS32582 capsule（high dose） or matched placebo

CS32582 capsule（high dose） or matched placebo，4 weeks

Intervention Type DRUG

CS32582 capsule（low dose）

CS32582 capsule（low dose），12 weeks

Intervention Type DRUG

CS32582 capsule（medium dose）

CS32582 capsule（medium dose），12 weeks

Intervention Type DRUG

CS32582 capsule（high dose）

CS32582 capsule（high dose），12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntarily sign the informed consent form (ICF) after fully understanding the trial.
* Age 18-70 years (inclusive) at consent, any gender
* Clinically diagnosed with chronic plaque psoriasis, defined as disease duration ≥ 6 months at screening.
* Stable plaque psoriasis at screening, defined as no significant flare-ups or morphological changes during the 6 months prior to screening (investigator-assessed).
* Moderate-to-severe disease at screening/randomization: PASI≥12, sPGA≥3, and BSA≥10%;
* Candidate for phototherapy or systemic therapy per investigator's judgment.
* Women of childbearing potential and males: Agreement to use highly effective contraception from consent until 30 days post-last dose.

Exclusion Criteria

* Forms of psoriasis other than plaque-type (e.g., erythrodermic, pustular, guttate, or drug-induced psoriasis) .
* Presence of other skin conditions that in the judgement of the Investigator could interfere with study assessment.
* Immune-mediated diseases requiring systemic therapy (e.g., inflammatory bowel disease), except NSAIDs.
* History of severe drug allergies.
* Major surgery within 2 months before randomization or planned during the study.
* Drug/alcohol abuse within 6 months before screening.
* Uncontrolled hypertension at screening (SBP \>160 mmHg or DBP \>100 mmHg).
* Myocardial infarction, unstable angina, TIA, stroke, PCI, or CABG within 6 months before screening.
* NYHA Class III/IV heart failure at screening.
* History of malignancy or lymphoproliferative disorders within 5 years (exceptions: basal cell carcinoma, localized squamous cell carcinoma, or cervical carcinoma in situ cured ≥1 year).
* Prosthetic joint infection (unless prosthesis removed/replaced ≥2 months before randomization).
* History of opportunistic infections (e.g., PJP, histoplasmosis, coccidioidomycosis).
* Active/latent TB infection (positive IGRA without clinical manifestations).
* Herpes infection:a) Active herpes zoster/simplex (HSV-1/2) at screening;b) History of severe herpes (disseminated disease, multidermatomal HSV, encephalitis, ophthalmic herpes, or recurrent zoster \[≥2 episodes in 2 years\]).
* History of severe bacterial, fungal, or viral infection requiring hospitalization for IV antibiotic or antiviral administration within 2 months before randomization.
* History of live vaccine administration within 2 months before randomization or plans to receive a live vaccine during the study period.
* Evidence of active infection and/or febrile illness requiring systemic anti-infective therapy within 2 weeks before randomization.
* Abnormal virology at screening:

* HBsAg(+) or HBcAb(+) with detectable HBV-DNA
* HCV Ab(+) with detectable HCV-RNA
* History of HIV infection or HIV Ab(+)
* Treponema pallidum Ab(+) with positive RPR/TRUST
* Prior use of TYK2 inhibitors (e.g., deucravacitinib).
* Use of any of the following therapeutic agents within 6 months before randomization:

* IL-12/23, IL-17, or IL-23 inhibitors (ustekinumab, secukinumab, tildrakizumab, ixekizumab, guselkumab)
* Rituximab or other B-cell depleting agents
* Leflunomide
* Use of any of the following therapeutic agents within 3 months before randomization: Integrin pathway modulators (natalizumab) or B/T-cell modulators (alemtuzumab, abatacept, vedolizumab).
* Use of TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab) within 2 months before randomization.
* Any biologic psoriasis therapy within 3 months or 5 half-lives (whichever longer) before randomization.
* Use of systemic non-biologic psoriasis agents and/or any systemic immunosuppressants within 4 weeks before randomization, including but not limited to: apremilast, methotrexate, azathioprine, cyclosporine, JAK inhibitors, 6-thioguanine, mercaptopurine, mycophenolate, hydroxyurea, tacrolimus, oral/injectable corticosteroids, retinoids, calcitriol/analogs, psoralen, sulfasalazine, fumarates).
* Use of Lithium, antimalarials, or intramuscular gold preparations within 4 weeks before randomization.
* Use of any botanical agents for the treatment of psoriasis or other immune disorders within 4 weeks before randomization, including herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals.
* Received phototherapy within 4 weeks before randomization.
* Use of medicated shampoos and/or body washes within 2 weeks before randomization, including but not limited to products containing: corticosteroids, coal tar, \>3% salicylic acid, vitamin D3 analogs.
* Use of any topical agents that may affect psoriasis symptoms within 2 weeks before randomization.
* Received any investigational therapy within 30 days or 5 half-lives (whichever is longer) before randomization, OR current participation in other trial.
* Laboratory values meeting any of the following criteria during screening or before randomization:

* Liver: ALT/AST ≥3×ULN; total bilirubin \>2×ULN
* Hematology: WBC \<3.0×10⁹/L (3000/mm³); ANC \<1.0×10⁹/L (1000/mm³); lymphocyte count \<0.5×10⁹/L (500/mm³); platelets \<100×10⁹/L (100,000/mm³); hemoglobin \<9.0 g/dL (90 g/L)
* Renal: eGFR \<60 mL/min/1.73m² (CKD-EPI equation)
* Pregnant or lactating women.
* Any condition deemed unsuitable by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.